SCHEMBL5714935

SCHEMBL5714935

Cc1cccnc1Cc1ccc(OC(=O)N2CCN(c3ccc(C(=O)O)cn3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 5/20 0.49
HRH3 Q9Y5N1 1/20 0.44
PANK3 Q9H999 1/20 0.44
HSD17B10 Q99714 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
TRPA1 O75762 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
P2RY12 Q9H244 1/20 0.42
TRPV1 Q8NER1 2/20 0.41
ME2 P23368 1/20 0.41
ME1 P48163 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714124 0.92 ME2 (0.44) SMOHRH3PANK3HSD17B10NPSR1
SCHEMBL5715581 0.90 SMO (0.47) SMOHRH3PANK3HSD17B10NPSR1
SCHEMBL5714523 0.89 SMO (0.47) SMOPANK3HSD17B10NPSR1HPGD
SCHEMBL5715220 0.88 TRPA1 (0.52) SMOPANK3HSD17B10NPSR1HPGD
SCHEMBL5715353 0.88 CHRM1 (0.46) SMOHRH3PANK3HSD17B10NPSR1
SCHEMBL5714600 0.87 HSD17B10 (0.57) SMOHSD17B10NPSR1HPGDL3MBTL1
SCHEMBL5714595 0.86 SMN1; SMN2 (0.59) SMOHSD17B10HPGDL3MBTL1SMN1; SMN2
SCHEMBL5715130 0.86 KDM4E (0.45) SMOALDH1A1TSHRMAPK1KDM4E
SCHEMBL5714370 0.84 SMO (0.49) SMOHRH3PANK3HSD17B10NPSR1
SCHEMBL5714740 0.83 SIGMAR1 (0.41) SMOLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC SMO 2616/4885HRH3 1098/4885PANK3 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.